EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%

Abstract Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1 >50% overexpression.